Treatments

Progress in developing drugs to treat FH

Producing new drugs is a time-consuming and costly business. A 2014 report from the Tufts Centre for the Study of Drug Development (CSDD) reported in Scientific American calculated that the cost of developing a prescription drug that gains market approval was USD 2.6 billion, a 145% increase, correcting for inflation, over the estimate the centre made in 2003. The report noted the 10 plus years a drug spends in development. CSSD observed that despite intense efforts to improve efficiency in pharmaceutical research and development, higher costs result from the increased complexity of clinical trials, a greater focus on chronic and degenerative diseases and tests for insurers seeking comparative drug effectiveness data – as well as the high cost of unsuccessful drug development projects.

Newsletter

Newsletter

Join our mailing list to receive the regular FH Europe eFlash

Great! Check your mailbox to confirm your subscription

FH Europe is registered as a charity; Charity number 1170731, registered in England and Wales.

FH Europe is registered as a charity; Charity number 1170731, registered in England and Wales.

FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Regeneron, Akcea Therapeutics Inc. and Amryt
Site by: Vovi Web Design